MEIP News and Press, MEI Pharma Inc. From 03/08/22

This article focuses on the major influences towards a biotech company's share price, rather than their value or opportunity. These catalysts will be important to consider when timing your entry and exit points. This article will be the last that focuses on evaluating individual h...

MEI Pharma press release (NASDAQ:MEIP): FQ2 GAAP EPS of -$0.09. Revenue of $18.22M (+98.7% Y/Y). For further details see: MEI Pharma GAAP EPS of -$0.09, revenue of $18.22M

-MEI Begins Third Fiscal Quarter with ~$186 Million in Cash- -Quarter Highlighted by Data from the Global Phase 2 TIDAL Study Evaluating Zandelisib as a Single Agent in Patients with Relapsed or Refractory Follicular Lymphoma- MEI Pharma, Inc. (Nasdaq: MEIP), a late-...

MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced the expansion of its management team with the addition of two experienced industry executives. Alejandro Ricart, M.D., joins MEI as senior vice president, ...

MEIP's lead asset is zandelisib, an oral PI3K delta inhibitor. In two studies in Follicular lymphoma, zandelisib has shown strong data. What should concern MEI is the FDA's issue with safety for the entire PI3K delta class. For further details see: MEI Pharma: Another PI...

MEI Pharma (NASDAQ:MEIP) has announced an underwritten public offering of 17.5M shares of its common stock. Terms of the offering are yet to be determined. Underwriters may be granted a 30-day option to purchase up to an additional 15% of the shares of common stock issued in the offering. Net...

If you’re looking for the next round of penny stocks to buy right now, you’ve landed in the right place. Today we’re looking at three stocks that can be purchased for less than $4 right now. Whether they’re worth the risk or not is something I’ll leave up ...

Dollar Tree (NASDAQ:DLTR) represented one of the highest-profile names making headlines in Tuesday's pre-market action. Shares retreated following a downgrade from Goldman Sachs. JinkoSolar (NYSE:JKS) also experienced selling pressure in pre-market trading, weighed down by lackluster revenue ...

MEI Pharma (NASDAQ:MEIP) and Kyowa Kirin (OTCPK:KYKOF) gains 10.2% premarket after announcing that the Phase 2 TIDAL study evaluating zandelisib as a single agent for follicular lymphoma (FL) patients who received at least two prior systemic therapies demonstrated a 70.3% objective ...

– Zandelisib Demonstrated 70.3% Objective Response Rate; 35.2% Achieved Complete Response – – 9.9% of Patients Discontinued Therapy Due to a Drug Related Adverse Event – – MEI to Host Webcast Today at 8:00am Eastern Time – ...